Trial Search Results

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Device: Intermittent theta-burst stimulation (iTBS)




Inclusion Criteria:

   - Male or female, 18 to 75 years of age.

   - Able to provide informed consent.

   - Diagnosed with Major Depressive Disorder (MDD) or bipolar affective disorder 2 and
   currently experiencing a Major Depressive Episode (MDE).

   - prior exposure to rTMS

   - Participants must qualify as "moderate or severe treatment refractory" using the
   Maudsley staging method.

   - Participants may continue antidepressant regimen, but must be stable for 6 weeks prior
   to enrollment in the study. They must maintain that same antidepressant regimen
   throughout the study duration.

   - Participants are required to have a stable psychiatrist for the duration of study

Exclusion Criteria:

   - History of MI, CABG, CHF, or other cardiac history

   - Any neurological conditions

   - History of epilepsy

   - OCD

   - Independent sleep disorder

   - Autism Spectrum Disorder

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Claudia Tischler, BA